Adjuvant pembrolizumab improves disease-free survival in kidney cancer
Adjuvant pembrolizumab (Keytruda) extended disease-free survival (DFS) in patients with renal cell carcinoma (RCC), according to findings from the phase 3 KEYNOTE-564 trial announced today by Merck (MSD), the developer of the PD-1 inhibitor.
Original Article Source Credits: Urology Times , https://www.urologytimes.com/
Article Written By: Jason M. Broderick
Original Article Posted on: April 8, 2021
Link to Original Article: https://www.urologytimes.com/view/adjuvant-pembrolizumab-improves-disease-free-survival-in-kidney-cancer